Kerry Knievel November 20, 2019

Cephalalgia, Ahead of Print.
BackgroundLasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. Post-hoc integrated analyses evaluated the efficacy of lasmiditan in patients who reported a good or insufficient response to triptans and in those who were triptan naïve.MethodsSubgroups of patients reporting an overall response of “good” or “poor/none” to the most recent use of a triptan at baseline (defined as good or insufficient responders, respectively) and a triptan-naïve subpopulation were derived from combined study participants randomized to receive lasmiditan 50 mg (SPARTAN only), 100 mg or 200 mg, or placebo, as the first dose.… Read More...

Stephen D. Silberstein, Stephen B. Shrewsbury, John Hoekman November 18, 2019


To provide a narrative review of clinical development programs for non‐oral, non‐injectable formulations of dihydroergotamine (DHE) for the treatment of migraine.


Dihydroergotamine was one of the first “synthetic drugs” developed in the 20th century for treating migraine. It is effective and recommended for acute migraine treatment.… Read More...

Holland C. Detke, Brian A. Millen, Qi Zhang, Karen Samaan, Jessica Ailani, David W. Dodick, Sheena K. Aurora November 17, 2019


To evaluate onset of effect of galcanezumab in patients with episodic migraine.


Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related peptide and is indicated for preventive treatment of migraine.


Data on the primary outcome measure were analyzed from 2 previously published double‐blind, Phase 3 studies (EVOLVE‐1 [N = 858] and EVOLVE‐2 [N = 915]) wherein adult patients with episodic migraine were randomized to receive monthly subcutaneous injections of galcanezumab 120 mg (with 240‐mg loading dose) or 240 mg or placebo for up to 6 months.… Read More...

Andoird App